Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.4 Million USD | -29.05% |
| 2022 | 3.38 Million USD | 48.37% |
| 2021 | 2.28 Million USD | -24.16% |
| 2020 | 3.01 Million USD | -25.17% |
| 2019 | 4.02 Million USD | -4.82% |
| 2018 | 4.22 Million USD | -8.13% |
| 2017 | 4.6 Million USD | -14.91% |
| 2016 | 5.41 Million USD | 116.43% |
| 2015 | 2.5 Million USD | 13.64% |
| 2014 | 2.19 Million USD | -9.75% |
| 2013 | 2.43 Million USD | 37.49% |
| 2012 | 1.77 Million USD | 1156.79% |
| 2011 | 141.06 Thousand USD | 323.77% |
| 2010 | 33.28 Thousand USD | -91.24% |
| 2009 | 380 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 249.97 Thousand USD | 3.34% |
| 2024 Q1 | 241.89 Thousand USD | -61.44% |
| 2023 Q4 | 627.28 Thousand USD | 32.48% |
| 2023 Q1 | 612.83 Thousand USD | 2.2% |
| 2023 Q3 | 473.49 Thousand USD | -59.75% |
| 2023 Q2 | 1.17 Million USD | 91.98% |
| 2023 FY | 2.4 Million USD | -29.05% |
| 2022 Q3 | 503.71 Thousand USD | -72.0% |
| 2022 Q1 | 487.33 Thousand USD | 33.42% |
| 2022 FY | 3.38 Million USD | 48.37% |
| 2022 Q4 | 599.64 Thousand USD | 19.05% |
| 2022 Q2 | 1.79 Million USD | 269.16% |
| 2021 Q2 | 599.83 Thousand USD | -3.66% |
| 2021 FY | 2.28 Million USD | -24.16% |
| 2021 Q1 | 622.63 Thousand USD | -3.97% |
| 2021 Q4 | 365.24 Thousand USD | -47.59% |
| 2021 Q3 | 696.94 Thousand USD | 16.19% |
| 2020 Q1 | 743.03 Thousand USD | -10.61% |
| 2020 FY | 3.01 Million USD | -25.17% |
| 2020 Q2 | 635.15 Thousand USD | -14.52% |
| 2020 Q3 | 986.01 Thousand USD | 55.24% |
| 2020 Q4 | 648.41 Thousand USD | -34.24% |
| 2019 Q4 | 831.26 Thousand USD | -37.8% |
| 2019 FY | 4.02 Million USD | -4.82% |
| 2019 Q1 | 850.23 Thousand USD | -20.25% |
| 2019 Q2 | 1 Million USD | 18.55% |
| 2019 Q3 | 1.33 Million USD | 32.58% |
| 2018 Q3 | 1.05 Million USD | 26.93% |
| 2018 Q1 | 1.28 Million USD | 53.95% |
| 2018 FY | 4.22 Million USD | -8.13% |
| 2018 Q4 | 1.06 Million USD | 1.32% |
| 2018 Q2 | 828.95 Thousand USD | -35.35% |
| 2017 Q2 | 2.17 Million USD | 290.63% |
| 2017 Q1 | 557.51 Thousand USD | -11.9% |
| 2017 FY | 4.6 Million USD | -14.91% |
| 2017 Q4 | 832.95 Thousand USD | -19.57% |
| 2017 Q3 | 1.03 Million USD | -52.45% |
| 2016 Q3 | 1.31 Million USD | -36.53% |
| 2016 Q1 | 1.4 Million USD | 18.52% |
| 2016 Q4 | 632.81 Thousand USD | -51.72% |
| 2016 FY | 5.41 Million USD | 116.43% |
| 2016 Q2 | 2.06 Million USD | 47.29% |
| 2015 Q3 | 469.47 Thousand USD | -5.02% |
| 2015 FY | 2.5 Million USD | 13.64% |
| 2015 Q4 | 1.18 Million USD | 151.99% |
| 2015 Q2 | 494.26 Thousand USD | 14.0% |
| 2015 Q1 | 433.55 Thousand USD | 180.4% |
| 2014 Q2 | 836.87 Thousand USD | 45.18% |
| 2014 FY | 2.19 Million USD | -9.75% |
| 2014 Q1 | 576.43 Thousand USD | 14.63% |
| 2014 Q4 | 154.61 Thousand USD | -75.53% |
| 2014 Q3 | 631.99 Thousand USD | -24.48% |
| 2013 Q4 | 502.87 Thousand USD | 17.54% |
| 2013 FY | 2.43 Million USD | 37.49% |
| 2013 Q1 | 1.02 Million USD | -35.52% |
| 2013 Q2 | 481.59 Thousand USD | -53.03% |
| 2013 Q3 | 427.81 Thousand USD | -11.17% |
| 2012 Q4 | 1.59 Million USD | 31.34% |
| 2012 FY | 1.77 Million USD | 1156.79% |
| 2012 Q1 | -427.21 Thousand USD | -1524.05% |
| 2012 Q2 | 830.96 Thousand USD | 294.51% |
| 2012 Q3 | 1.21 Million USD | 45.71% |
| 2011 Q3 | 30 Thousand USD | 0.0% |
| 2011 FY | 141.06 Thousand USD | 323.77% |
| 2011 Q4 | 30 Thousand USD | 0.0% |
| 2010 FY | 33.28 Thousand USD | -91.24% |
| 2010 Q4 | 30 Thousand USD | 0.0% |
| 2010 Q3 | 30 Thousand USD | 0.0% |
| 2009 FY | 380 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -80.087% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 52.302% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 91.862% |
| Nascent Biotech, Inc. | 2.22 Million USD | -7.85% |
| Rebus Holdings, Inc. | 664 Thousand USD | -262.189% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.545% |
| Qrons Inc. | 643.67 Thousand USD | -273.624% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -517.337% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.813% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -478.834% |
| Skye Bioscience, Inc. | 13.54 Million USD | 82.248% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.229% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 51.098% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -818.875% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.191% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 17.533% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -60.126% |
| Mesoblast Limited | 5.9 Million USD | 59.252% |
| Marizyme, Inc. | 19.23 Million USD | 87.5% |
| Genus plc | 147.7 Million USD | 98.372% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 72.607% |
| Pharming Group N.V. | 225.49 Million USD | 98.933% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -17.388% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -79.266% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 71.16% |
| ContraFect Corporation | 56.88 Million USD | 95.773% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 45.45% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -62.633% |
| IMV Inc. | 37.7 Million USD | 93.622% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 13.813% |
| MultiCell Technologies, Inc. | 567.42 USD | -423736.664% |
| ONE Bio Corp. | 6.44 Million USD | 62.679% |
| Accustem Sciences Inc. | 3.74 Million USD | 35.807% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.202% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -352.088% |
| Q BioMed Inc. | 3.43 Million USD | 30.021% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.269% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 8.471% |
| Biomind Labs Inc. | 994.18 Thousand USD | -141.901% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.579% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -36.669% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 64.202% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -28.994% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9719.736% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 84.979% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -31.052% |
| GB Sciences, Inc. | 1.42 Million USD | -69.301% |
| Alpha Cognition Inc. | 9.7 Million USD | 75.221% |
| HST Global, Inc. | 140.9 Thousand USD | -1606.753% |
| CSL Limited | 3.44 Billion USD | 99.93% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -113.789% |
| Halberd Corporation | 74.84 Thousand USD | -3113.348% |
| Enzolytics Inc. | 2.17 Million USD | -10.343% |
| Agentix Corp. | 1.37 Million USD | -75.318% |
| Resverlogix Corp. | 12.71 Million USD | 81.081% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 34.124% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.843% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -130.358% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -52.273% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 29.37% |
| AVAX Technologies, Inc. | 7.31 Million USD | 67.102% |
| Zenith Capital Corp. | 8.94 Million USD | 73.108% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.709% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -13704.799% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 2.052% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1302.22% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -25.198% |
| Kadimastem Ltd | 2.41 Million USD | 0.215% |
| Helix BioMedix, Inc. | 1.97 Million USD | -21.952% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 77.869% |
| BioStem Technologies, Inc. | 22.97 Million USD | 89.532% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1225.142% |
| LadRx Corporation | 3.81 Million USD | 36.908% |
| Cell Source, Inc. | 4.32 Million USD | 44.399% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -160.412% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -160.412% |
| NovAccess Global Inc. | 2.46 Million USD | 2.506% |
| Affymax, Inc. | 39.38 Million USD | 93.894% |
| Itoco Inc. | 919.14 Thousand USD | -161.65% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 43.259% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -114.918% |
| Mobile Lads Corp. | 554.54 Thousand USD | -333.676% |
| CytoDyn Inc. | 18.05 Million USD | 86.682% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9455.143% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -992.764% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -69.386% |
| SYBLEU INC | 160.87 Thousand USD | -1394.899% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -32.407% |
| International Stem Cell Corporation | 5.27 Million USD | 54.374% |
| Bioxytran, Inc. | 3.82 Million USD | 37.046% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4468.47% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -11721.924% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.369% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -48.636% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -226.831% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 22.696% |
| Neutra Corp. | 243.82 Thousand USD | -886.352% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 86.224% |
| PureTech Health plc | 144.59 Million USD | 98.337% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 88.263% |
| IXICO plc | 4.7 Million USD | 48.907% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 72.662% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.958% |
| CSL Limited | 3.89 Billion USD | 99.938% |
| Cellectis S.A. | 97.32 Million USD | 97.529% |